23 JULY 2019 INVESTOR OPEN DAY CEO PAUL SWINNEY CFO LIZ DIXON The - PowerPoint PPT Presentation

23 JULY 2019 INVESTOR OPEN DAY CEO PAUL SWINNEY CFO LIZ DIXON

The World of Infection Prevention Medical Devices Skin Surfaces Water 2

The World of Chlorine Dioxide Pro ropri rietary Formu mulation on Comm mmod odity High C Conc ncent ntration Low C Concentr trati tion Suitab able For S Special alit ity Applic icat atio ions: s: Suitab able F For Indust strial al A Applicatio ions: s: Medical Devices Paper Bleaching Surfaces Water Disinfection 3

How Do We Make Chlorine Dioxide Sodium Chlorine Sodium Salt Citric Acid Chlorite Dioxide Citrate 4

Multiple User Sites in Hospitals Worldwide Device ce: Nas asendosc scope Diagno gnosis: : Cleft Pa t Palate te Department nt: : Ear ar, Nose se & T Throat Device ce: End Endocavity Pro robe Diagno gnosis: : End Endometriosis Department nt: : Ultras asound Device ce: Lar Laryngoscope Pur urpo pose: e: Intuba bati tion Department nt: : Acci cide dent & & Emer ergen ency 5

Regulation Drives Demand Semi-Critical Invasive Device Classification High-level Disinfection 6

Tristel’s Chlorine Dioxide ClO 2 (Core) ClO2 Medical Medical devices Non ClO 2 (Non-core) £22.7m Devices £3.3m Other ClO2 Other £2.2m £20.5m 7

Sales Growth: Core vs Non-Core £30,000,000 CORE + 2 24% 4% £25,000,000 ClO2 Medical Devices £20,000,000 ClO2 Other NON-CORE £15,000,000 Non ClO2 £10,000,000 £5,000,000 + 11% 11% - 5% 5% £0 2015-16 2016-17 2017-18 2018-19 8

Intellectual property protection Manufacturers Compatibility (55) Individual Device Compatibility (1,845) Published Papers (29) Patents Guidelines (19) (6) Families (233) Grants (66) Applications In Progress Proprietary Formulation 9

The Key Dynamics of The Business + International: growing fast (2019: +25%) + Medical devices (ClO2): growing fast (2019: +24%) + Surfaces (ClO2): picking up pace (2019: +11%) - Growth held back by declining non-core sales (2019: -5%) 10

Total Sales Growth History CAGR 17% £30,000,000 £25,000,000 £20,000,000 £15,000,000 £10,000,000 £5,000,000 £0 11

Total Sales Growth History £30,000,000 UK sales International sales £25,000,000 £20,000,000 £15,000,000 £10,000,000 £5,000,000 £0 12

International Sales Growth History CAGR 53% £16,000,000 £14,000,000 £12,000,000 £10,000,000 £8,000,000 £6,000,000 £4,000,000 £2,000,000 £0 13

International Sales Growth History £16,000,000 Distributors Europe Direct Asia Pacific Direct £14,000,000 £12,000,000 £10,000,000 £8,000,000 £6,000,000 £4,000,000 £2,000,000 £0 14

Global Distributors 15

Global Subsidiaries Approvals in process Active 16

ClO2 Medical Devices CAGR 39% £25,000,000 £20,000,000 £15,000,000 £10,000,000 £5,000,000 £0 17

Sales Performance Vs Target 2016-2019 £27,000,000 15% £25,000,000 10% £23,000,000 15% £21,000,000 10% 15% £19,000,000 10% £17,000,000 £15,000,000 2015-16 2016-17 2017-18 2018-19 Sales actual 18

Profitability Target 2016-2019 Targeted PBT* margin: 17.5% Actual PBT* margin: 2016-17 20% 2017-18 21% 2018-19 21% **before share based payments and after expensing USA regulatory costs 19

Profit* £8,000,000 £7,000,000 £6,000,000 £5,000,000 £4,000,000 £3,000,000 £2,000,000 £1,000,000 £0 2015-16 2016-17 2017-18 2018-19 Adjusted PBT Brokers forecast *before tax and share based payments 20

Cash 2017-2019 Cash generated: £19m Cash utilisation: Investments & acquisitions £9m Capital expenditure £2m Dividends £7m Working capital & tax £3m Net cash reduction: £2m 21

2019 Achievements A high growth, broadly based business. Three year financial targets beaten. Surplus cash re-invested into sales and profit growth. 22

Major Initiatives United States Surfaces Point of Care Julija Shabanova Elanor Dixon Ultrasound (POCUS) Bart Leemans Women’s Health 3T Crystel Danielle Smith Esther Jansen Rob Lewis 23

United States Semi mi-crit itic ical devic ices Hig igh- leve vel dis isinfectant DeNovo vo pathway y Usability a and human f n factors study: Pre re-subm bmission on review u ew underway Focus on n Ultr ltrasound Spe pend t to dat ate £1. £1.5m 24

Thank you Q&A 25